强强联合 金斯瑞生物与ABL Bio达成双特异性抗体开发战略合作

2019-11-19 不详 美通社

全球领先的生物医药CDMO公司南京金斯瑞生物科技今日宣布,与专注于开发用于免疫肿瘤和神经退行性疾病的治疗药物的韩国生物技术公司ABL Bio签署协议,双方针对两个双特异性抗体项目开发达成战略合作。 ABL Bio 首席执行官 Sang Hoon Lee博士与金斯瑞生物药事业部首席执行官 Brian Min 博士出席此次签约仪式 根据合作协议,金斯瑞将授权ABL Bio使用一种靶

全球领先的生物医药CDMO公司南京金斯瑞生物科技今日宣布,与专注于开发用于免疫肿瘤和神经退行性疾病的治疗药物的韩国生物技术公司ABL Bio签署协议,双方针对两个双特异性抗体项目开发达成战略合作。

ABL Bio 首席执行官 Sang Hoon Lee博士与金斯瑞生物药事业部首席执行官 Brian Min 博士出席此次签约仪式
ABL Bio 首席执行官 Sang Hoon Lee博士与金斯瑞生物药事业部首席执行官 Brian Min 博士出席此次签约仪式

根据合作协议,金斯瑞将授权ABL Bio使用一种靶向肿瘤的单域抗体、一种单克隆抗体以及金斯瑞SMAB (Single-Domain Antibody fused to Monoclonal Ab) 双特异性抗体平台开发多个双特异性抗体分子,并委托金斯瑞为双特异性抗体分子的临床前药学研究和临床样品生产CDMO服务的独家供应商,加速肿瘤免疫抗体创新药物的开发。金斯瑞将为此项目的开发提供持续支持与服务。金斯瑞将获得来自ABL Bio的首付款和里程碑付款,以及产品上市后全球销售额计算的销售提成。双方将充分利用各自优势及资源,进一步丰富ABL Bio 在双特异性抗体研发领域管线,以及进一步加强ABL Bio 在肿瘤研究领域的全球领先地位。

全球领先的生物医药CDMO公司南京金斯瑞生物科技今日宣布,与专注于开发用于免疫肿瘤和神经退行性疾病的治疗药物的韩国生物技术公司ABL Bio签署协议,双方针对两个双特异性抗体项目开发达成战略合作。

“我们很高兴能与金斯瑞这样一家快速发展的企业合作,金斯瑞近年间发展迅速,在抗体药研发领域已经助力多家公司取得成绩。”ABL Bio 首席执行官Sang Hoon Lee博士参加了此次签约仪式说,“我们非常期待凭借金斯瑞的双抗平台出色的成药性以及便捷的生产流程,加速推动ABL Bio创新免疫疗法的开发以及新药上市,此次强强联合,将进一步丰富我们的双特异性抗体研发管线,为进军全球肿瘤免疫和神经退行性疾病领域领先梯队助力。”

“我们非常荣幸能与像ABL Bio一样在双特异性抗体领域拥有丰富经验的公司进行合作,这说明了,金斯瑞生物药研发服务已经受到越来越多的国际知名公司的认可,”金斯瑞生物药事业部首席执行官Brian Min博士说道,“金斯瑞在生物药研发领域拥有非常丰富的研发经验和非常强大的团队,我们希望可以与越来越多同ABL Bio一样具有实力的公司,利用自身强大的研发优势,强强联合,加速创新抗体药的开发进程。”

关于金斯瑞生物SMAB平台:

双特异性抗体是含有两种特异性抗原结合位点的人工抗体,相对单克隆抗体,其新作用机理在研究中被证明具有更好的疗效和更高的安全性。金斯瑞的SMAB (Single-Domain Antibody fused to Monoclonal Ab) 双特异性抗体平台由单域抗体融合单克隆抗体构成,与其他双抗平台不同,SMAB平台具有无任何序列突变、工程化程度最低的特色,是全球业界最天然的双特异性抗体。这一天然属性击破了传统双抗平台免疫原性风险高、成药性差、规模化生产难的诸多壁垒,仅需3-5个月即可完成双抗分子开发,14-15个月即可完成临床前工艺开发,开发过程高效,且成药性与单克隆抗体相当。此外,单域抗体的灵活性使SMAB双抗分子可与酶、离子通道等“隐藏的”表位结合,还能灵活地运用“即插即用”的方式构建多价分子,极大的拓展了其应用价值。

关于ABL Bio: 

ABL Bio Inc. (298380:KQ)是一家专注肿瘤免疫和神经退行性疾病抗体疗法开发的韩国生物技术公司。ABL Bio于2016年成立,三年内成功募资近1.7亿美元,并在2018年12月登陆韩国证券交易所(KOSDAQ)。公司在研产品ABL001,即靶向VEGF和DLL4的肿瘤治疗双特异性抗体,目前正处于一期临床试验阶段。ABL Bio正在积极开发多个围绕4-1BB靶点的双特异性抗体和多个基于双特异性抗体的全球首创(First-in-Class)和同类最佳(Best-in-Class)免疫疗法。在神经退行性疾病领域,ABL Bio正利用其双特异抗体专长,开发旨在最大化提高血脑屏障穿透性和疗效的新一代产品。现阶段,公司研发进展最快的产品ABL301,是靶向α-突触核蛋白的双特异性抗体,可以通过受体介导的转胞吞作用穿透血脑屏障,用于治疗帕金森。

关于金斯瑞生物科技:

金斯瑞生物科技股份有限公司(股票代码HK01548)是全球化的生物科技集团公司。集团植根于领先的基因合成技术,业务范围涵盖生命科学服务及产品、生物酶及合成生物学产品、生物药开发与生产服务及细胞治疗四大领域。

金斯瑞成立于2002年,并于2015年在港交所主板挂牌上市。集团总部位于中国南京,运营实体遍布大中华区、北美区、欧洲区及亚太区,并以此为依托,为全球160多个国家和地区的30多万客户提供优质、便捷、可靠的服务与产品。

目前,金斯瑞在全球拥有超过2900名员工,其中34%以上的员工拥有硕士或博士学位。金斯瑞拥有多项知识产权及技术机密,其中包含100多项授权专利及270多项专利申请。金斯瑞与全球生命科学领域的科学家们建立了紧密的联系,截至2019年6月30日,有超过40,300篇经国际同业审阅的学术期刊文献引述了金斯瑞的服务及产品。

秉承“用生物技术使人和自然更健康”的企业使命,金斯瑞将一如既往地致力于成为最受信赖的生物科技公司。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918928, encodeId=9dfd1918928e2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Sep 19 14:32:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899343, encodeId=28cc189934341, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Nov 28 18:32:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025804, encodeId=97d9102580459, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Fri Nov 22 00:32:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478255, encodeId=c5e014e82551e, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516497, encodeId=ff07151649e50, content=<a href='/topic/show?id=a6ba96195c5' target=_blank style='color:#2F92EE;'>#金斯瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96195, encryptionId=a6ba96195c5, topicName=金斯瑞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f12410973048, createdName=12498da4m35(暂无昵称), createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526459, encodeId=5641152645944, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375564, encodeId=5c443e5564f9, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Nov 20 09:05:44 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
    2020-09-19 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918928, encodeId=9dfd1918928e2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Sep 19 14:32:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899343, encodeId=28cc189934341, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Nov 28 18:32:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025804, encodeId=97d9102580459, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Fri Nov 22 00:32:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478255, encodeId=c5e014e82551e, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516497, encodeId=ff07151649e50, content=<a href='/topic/show?id=a6ba96195c5' target=_blank style='color:#2F92EE;'>#金斯瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96195, encryptionId=a6ba96195c5, topicName=金斯瑞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f12410973048, createdName=12498da4m35(暂无昵称), createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526459, encodeId=5641152645944, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375564, encodeId=5c443e5564f9, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Nov 20 09:05:44 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918928, encodeId=9dfd1918928e2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Sep 19 14:32:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899343, encodeId=28cc189934341, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Nov 28 18:32:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025804, encodeId=97d9102580459, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Fri Nov 22 00:32:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478255, encodeId=c5e014e82551e, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516497, encodeId=ff07151649e50, content=<a href='/topic/show?id=a6ba96195c5' target=_blank style='color:#2F92EE;'>#金斯瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96195, encryptionId=a6ba96195c5, topicName=金斯瑞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f12410973048, createdName=12498da4m35(暂无昵称), createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526459, encodeId=5641152645944, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375564, encodeId=5c443e5564f9, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Nov 20 09:05:44 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
    2019-11-22 研发小兵

    双特异性抗体是热点,但是也不一定都有效!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1918928, encodeId=9dfd1918928e2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Sep 19 14:32:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899343, encodeId=28cc189934341, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Nov 28 18:32:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025804, encodeId=97d9102580459, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Fri Nov 22 00:32:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478255, encodeId=c5e014e82551e, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516497, encodeId=ff07151649e50, content=<a href='/topic/show?id=a6ba96195c5' target=_blank style='color:#2F92EE;'>#金斯瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96195, encryptionId=a6ba96195c5, topicName=金斯瑞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f12410973048, createdName=12498da4m35(暂无昵称), createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526459, encodeId=5641152645944, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375564, encodeId=5c443e5564f9, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Nov 20 09:05:44 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1918928, encodeId=9dfd1918928e2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Sep 19 14:32:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899343, encodeId=28cc189934341, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Nov 28 18:32:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025804, encodeId=97d9102580459, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Fri Nov 22 00:32:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478255, encodeId=c5e014e82551e, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516497, encodeId=ff07151649e50, content=<a href='/topic/show?id=a6ba96195c5' target=_blank style='color:#2F92EE;'>#金斯瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96195, encryptionId=a6ba96195c5, topicName=金斯瑞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f12410973048, createdName=12498da4m35(暂无昵称), createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526459, encodeId=5641152645944, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375564, encodeId=5c443e5564f9, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Nov 20 09:05:44 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1918928, encodeId=9dfd1918928e2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Sep 19 14:32:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899343, encodeId=28cc189934341, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Nov 28 18:32:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025804, encodeId=97d9102580459, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Fri Nov 22 00:32:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478255, encodeId=c5e014e82551e, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516497, encodeId=ff07151649e50, content=<a href='/topic/show?id=a6ba96195c5' target=_blank style='color:#2F92EE;'>#金斯瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96195, encryptionId=a6ba96195c5, topicName=金斯瑞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f12410973048, createdName=12498da4m35(暂无昵称), createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526459, encodeId=5641152645944, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375564, encodeId=5c443e5564f9, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Nov 20 09:05:44 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1918928, encodeId=9dfd1918928e2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Sep 19 14:32:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899343, encodeId=28cc189934341, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Nov 28 18:32:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025804, encodeId=97d9102580459, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Fri Nov 22 00:32:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478255, encodeId=c5e014e82551e, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516497, encodeId=ff07151649e50, content=<a href='/topic/show?id=a6ba96195c5' target=_blank style='color:#2F92EE;'>#金斯瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96195, encryptionId=a6ba96195c5, topicName=金斯瑞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f12410973048, createdName=12498da4m35(暂无昵称), createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526459, encodeId=5641152645944, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Wed Nov 20 15:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375564, encodeId=5c443e5564f9, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Nov 20 09:05:44 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
    2019-11-20 一天没事干

    很好的学习机会

    0